PHILADELPHIA, PA — Vittoria Biotherapeutics has announced the appointment of seasoned life sciences leader, Rosemary Mazanet, M.D., Ph.D., as its new Chief Medical Officer. Dr. Mazanet brings over two decades of C-suite leadership experience to the company, with an impressive track record in clinical development and strategic vision across both public and private sectors.
In her new role, Dr. Mazanet will be responsible for steering Vittoria’s clinical development strategy, including advancing the company’s lead candidate, VIPER-101, into the clinic. VIPER-101, a novel cell therapy, is being developed as a potential breakthrough treatment for patients with T-cell lymphoma.
“Dr. Mazanet’s extensive expertise in the oncology and hematology drug development ecosystem will be invaluable as we enter first-in-human studies for our lead program,” said Nicholas Siciliano, Ph.D., Vittoria’s Chief Executive Officer. “Her dedication to advancing novel therapeutics in oncology aligns perfectly with our mission to deliver groundbreaking cell therapies to patients in need.”
Dr. Mazanet expressed her enthusiasm for joining Vittoria, noting that the company’s innovative approach to CAR-T development could change the treatment landscape for T-cell lymphoma patients. “I am both inspired and excited to participate in Vittoria’s mission to turn the Senza5 CD5 knockout strategy into meaningful therapies across many disease states,” she added.
Prior to her appointment at Vittoria, Dr. Mazanet served as interim C-suite management and as a Strategic Advisor through her consultancy business, R Mazanet LLC. She also has substantial experience in public equity markets, having served as Managing Partner at Apelles Investment, LLC and head of Research at Oracle Partners LP. Earlier in her career, she led Clinical Development teams at Amgen, Inc., where her work resulted in multiple product approvals.
Currently an Emeritus Trustee at the University of Pennsylvania Health System, Dr. Mazanet also chairs the Executive Advisory Board for the Wharton Leonard Davis Institute. She holds a B.A. in biology from the University of Virginia, and an M.D. and Ph.D. from the University of Pennsylvania.
With Dr. Mazanet’s appointment, Vittoria Biotherapeutics is poised to further its mission to revolutionize cell therapies, bringing hope to patients with debilitating diseases such as T-cell lymphoma.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.